Diagnosis Of Dyscirculatory Encephalopathy And Metatron 4025 Hunter

Chronic forms of brain vascular pathology have become weightier in structure of cerebrovascular morbidity recently. Dyscirculatory encephalopathy (DE) has the biggest specific weigh among them. Clinical presentation of the disease is well studied, but at the same time problems of structural changes in brain detection, identifying of clinical and instrumental parallels and early defining of treatment optimal tactics became more and more urgent from the point of view of case-based medicine.

We can use Metatron system with 4.9 GHz generator frequency and Metatron 4025 hunter software for the diagnosis of DE.

Clinical picture of DE has progressing course. As analysis of NLS-research results proven, there are no pathognomonic changes in brain at the first stage of the disease, apparent neurological syndromes are not formed; subjective disorders, accompanied by light neurological semeiotics, predominate. The second stage of DE allows us to single out certain prevailing neurological syndromes – discoordination, pyramidal and amyostatic, which are manifested by presence of single or multiple gliosis nidi without tendency to merging, and that is the reason of patients’ professional and social adaptation significant decreasing. During the third stage of DE number of complaints significantly decreases, however neurological disorders become more apparent, they are presented in form of quite distinct and significant neurological syndromes, combining with apparent structural changes of brain, according to data acquired by NLS-research with REA.  

Thereby together with DE development, structural changes of brain tissue become more frequent: frequency and extent of atrophy, single cystic-nidal changes of brain become multiple.

Diagnostics of DE should be complex and include methods of neurovisualization, and one of the most informative and prospective of them we consider to be NLS-graphy with REA. Detection and evaluation of nidal and diffuse NLS-changes of brain tissue, in the context of clinical and sub-clinical neurological and neuropsychological data, create condition for early diagnostics of DE progredient forms and carrying out of active therapy targeted for prevention of further brain damage.